Format

Send to

Choose Destination
See comment in PubMed Commons below
Int Clin Psychopharmacol. 2004 Nov;19(6):351-3.

Aripiprazole and neuroleptic malignant syndrome.

Author information

1
Department of Psychiatry, Ailsa Hospital, Ayr, UK. nandini_dass@rediffmail.com

Abstract

Aripiprazole, an atypical antipsychotic with a novel method of action, has only recently been awarded a license in the UK. We report our first patient to receive this drug, who had treatment-resistant schizophrenia and developed neuroleptic malignant syndrome (NMS) with aripiprazole. To our knowledge, this is the first published case report involving aripiprazole and NMS in a potentially fatal medical emergency. Further experience with this drug should indicate whether this is an isolated case (as described with other atypical antipsychotics) or constitutes a more serious risk than that suggested by the relatively beneficial therapeutic profile described in the literature to date.

PMID:
15486522
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center